Childhood cancer

Childhood cancer

WHO / Yoshi Shimizu

Access to childhood cancer is inequitable between and within countries globally, resulting in hundreds of thousands of avoidable deaths each year. Survival probabilities for children with cancer are greater than 80% in high-income countries and less than 30% in many low- and middle-income countries. One of the root causes for this inequity is variable access to health products. Further, there is global consensus on the need to accelerate product development that meets the needs of children with cancer in all settings.

 In 2018, working alongside key multi-sectoral stakeholders including its strategic partner, St Jude Children’s Research Hospital, WHO Global Initiative for Childhood Cancer was launched. The initiative is now being implemented in more than 30 countries globally. One of the pillars in the CureAll technical package is increasing availability of and innovation in childhood cancer products.

WHO childhood cancer team is pleased to be working with GAP-f to convene an optimization group and to develop medium- and long-term priorities for medicine development, accelerating access to optimal formulations in the context of fragmented markets.

Portfolio products

7 products · PADO-childhood cancer
● Access list: 0    ● Priority list: 5    ● Watch list: 2
0 Access
5 Priority
2 Watch

PADO-childhood cancer priority list 5
(3–5 years horizon)
Methotrexate
Cyclophosphamide
Etoposide
Procarbazine
Temozolomide
PADO-childhood cancer watch list 2
Venetoclax
Venetoclax

PADO report

Paediatric drug optimization for cancer medicines: meeting report, January 2024
The goal of the Paediatric drug optimization for cancer exercise was to develop a PADO priority list of formulations to be prioritized with a time horizon...

Contact

Roberta Ortiz
Email: ortizr@who.int

André Ilbawi
Email: ilbawia@who.int

Related publications

Closing the childhood cancer survival gap through sustainable access to essential medicines: market shaping strategy (2026–2030)

Childhood cancer remains one of the starkest inequities in global health, with substantial differences in survival across countries and health systems....

Paediatric drug optimization standard procedure

The aim of this document is to provide guidance on how to undertake a paediatric drug optimization exercise and identify key priority products for research...

Related links